AbbVie Inc (ABBV)vsInnoviva Inc (INVA)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
INVA
Innoviva Inc
$22.52
+1.62%
HEALTHCARE · Cap: $1.58B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 14832% more annual revenue ($62.82B vs $420.69M). INVA leads profitability with a 119.9% profit margin vs 5.8%. INVA appears more attractively valued with a PEG of 0.32. INVA earns a higher WallStSmart Score of 85/100 (A-).
ABBV
Buy63
out of 100
Grade: C+
INVA
Exceptional Buy85
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for INVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 38 in profit
Keeps 120 of every $100 in revenue as profit
Strong operational efficiency at 40.1%
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : INVA
The strongest argument for INVA centers on PEG Ratio, P/E Ratio, Price/Book. Profitability is solid with margins at 119.9% and operating margin at 40.1%. Revenue growth of 10.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : INVA
The primary concerns for INVA are Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while INVA is a mature play — different risk/reward profiles.
INVA carries more volatility with a beta of 0.38 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
INVA scores higher overall (85/100 vs 63/100), backed by strong 119.9% margins and 10.6% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Innoviva Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?